ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Do analysts recommend ACAD or GMAB?

ACADIA Pharmaceuticals presently has a consensus target price of $27.88, indicating a potential upside of 23.56%. Genmab A/S has a consensus target price of $37.80, indicating a potential upside of 72.76%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Do institutionals and insiders believe in ACAD or GMAB?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, ACAD or GMAB?

ACADIA Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Does the media refer more to ACAD or GMAB?

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 9 articles in the media. Genmab A/S's average media sentiment score of 0.74 beat ACADIA Pharmaceuticals' score of 0.57 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ACAD or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to ACADIA Pharmaceuticals' net margin of 22.97%. Genmab A/S's return on equity of 18.08% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	22.97%	17.46%	10.75%
Genmab A/S	35.11%	18.08%	14.52%

Which has preferable earnings & valuation, ACAD or GMAB?

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	3.94	$226.45M	$1.37	16.47
Genmab A/S	$3.12B	4.50	$1.14B	$1.76	12.43

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 10 of the 15 factors compared between the two stocks.